A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma | MicrobiomeTrials
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2017-04-04Est. Completion: 2028-12-31
Enrollment target: 99 participants
Locations
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States